Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Global Type 1 diabetes market is set to grow at a compound annual growth rate (CAGR) of 13.3 per cent from $2.2 billion in ...

Levemir (insulin detemir) has a shorter duration of action than other long-acting basal insulins like Sanofi's Lantus (insulin glargine) and biosimilars and Novo Nordisk's newer product Tresiba ...

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying ... up at mealtimes with fast-acting insulins.

The picture shows an ampule of quick-acting ... high insulin prices is unconstitutional. In addition to UHC, the lawsuits filed in New Jersey name drug manufacturers Eli Lilly, Novo Nordisk ...

A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes ...

That said, Novo Nordisk has plenty of strengths as well. Its late-stage pipeline of diabetes/weight loss candidates is arguably stronger. It's also ahead of Lilly in getting a once-weekly insulin ...

Sikkim Casino entry fee Fountain Medical Completes $62 Million Series D Financing Novo Nordisk's Fiasp (rapid-acting insulin aspart) has been ap ...

Mahadev Online betting login Another new drug from Ionis, the leader in antisense oligonucleotides, has been approved for marketing in the ...

Novo Nordisk and Evotec select three projects from Boston University ... therapeutic candidates for the potential treatment of metabolic syndrome, including insulin resistance and type 2 diabetes. The ...

Novo Nordisk scientist Lotte Bjerre Knudsen paved the way for popular GLP-1 drugs like Ozempic. Her work in the 1990s was instrumental in turning short-acting hormones into long-acting drugs.